Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30793334 | 0.86 | KDM5A (0.34) | KDM5A | |
| SCHEMBL30793127 | 0.85 | AADAT (0.37) | KDM5A | |
| SCHEMBL20792765 | 0.78 | OGA (0.42) | — | |
| SCHEMBL29373389 | 0.77 | HTR2C (0.39) | KDM5A | |
| SCHEMBL12706924 | 0.77 | HTR2C (0.36) | KDM5A | |
| Hydrochloric Acid SCHEMBL20764966 | 0.77 | OGA (0.41) | — | |
| SCHEMBL16210607 | 0.76 | HTR2C (0.36) | KDM5A | |
| Hydrochloric Acid SCHEMBL1020680 | 0.76 | HTR2C (0.35) | KDM5A | |
| SCHEMBL23641909 | 0.69 | HTR2C (0.35) | — | |
| SCHEMBL17214083 | 0.68 | AADAT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | KDM5A 2920/4885HDAC1 2754/4885HDAC2 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.